Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.



Esperion Therapeutics (NASDAQ: ESPR) 10:37 AM ET on Mar 21, 2018
Last Price 76.84 Change +2.83(+3.824%) open 73.66 Day High 77.49 52-Week High 82.68
Volume 125,435 Previous Close 74.01 Day Low 73.60 52-Week Low 30.95

Press Releases

Load More